05:53 PM EDT, 07/31/2024 (MT Newswires) -- Exact Sciences ( EXAS ) reported a Q2 diluted loss Wednesday of $0.09 a share, narrowing from a loss of $0.45 a year earlier.

Analysts polled by Capital IQ expected a loss of $0.33.

Revenue in the quarter ended June 30 rose to $699.3 million from $622.1 million a year ago.

Analysts polled by Capital IQ expected $690.1 million.

Exact Sciences ( EXAS ) reiterated its full-year revenue guidance of $2.81 billion to $2.85 billion.

Analysts polled by Capital IQ expect $2.83 billion.

Shares of the company jumped 9.5% in recent after-hours trading.

Exact Sciences ( EXAS ) also entered an exclusive agreement to license TwinStrand Biosciences' patent estate in cell free nucleic acid sequencing.

Financial terms weren't disclosed in a statement Wednesday by TwinStrand.

TwinStrand's Duplex Sequencing technology is designed to improve the accuracy of cancer screening.

Price: 50.00, Change: +4.32, Percent Change: +9.46